Treatment of inflammation with anti-ICAM-1.
Rothlein
R
R
Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT.
Mainolfi
E A
EA
Kishimoto
T K
TK
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology; D018821:CD18 Antigens; D015815:Cell Adhesion Molecules / Q000276:immunology*; D006801:Humans; D007249:Inflammation / Q000628:therapy*; D018799:Intercellular Adhesion Molecule-1; D016028:Receptors, Leukocyte-Adhesion / Q000276:immunology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D018821:CD18 Antigens; D015815:Cell Adhesion Molecules; D016028:Receptors, Leukocyte-Adhesion; D018799:Intercellular Adhesion Molecule-1